Equities analysts forecast that ObsEva SA (NASDAQ:OBSV) will report earnings per share of ($0.23) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for ObsEva’s earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.24). ObsEva reported earnings per share of ($0.49) during the same quarter last year, which would suggest a positive year over year growth rate of 53.1%. The company is expected to issue its next quarterly earnings report on Thursday, November 4th.
According to Zacks, analysts expect that ObsEva will report full year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.02) to ($0.96). For the next year, analysts expect that the firm will report earnings of ($0.68) per share, with EPS estimates ranging from ($0.87) to ($0.48). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow ObsEva.
ObsEva (NASDAQ:OBSV) last announced its earnings results on Thursday, August 5th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01.
ObsEva stock opened at $3.34 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.64 and a quick ratio of 3.64. ObsEva has a 1-year low of $1.86 and a 1-year high of $5.55. The firm has a market capitalization of $192.23 million, a P/E ratio of -2.47 and a beta of 0.78. The company’s 50-day moving average is $2.77 and its 200 day moving average is $2.96.
Institutional investors have recently modified their holdings of the company. Morgan Stanley increased its holdings in ObsEva by 2,713.1% during the 2nd quarter. Morgan Stanley now owns 863,112 shares of the company’s stock valued at $2,615,000 after acquiring an additional 832,430 shares in the last quarter. Credit Suisse AG raised its holdings in ObsEva by 5.0% in the second quarter. Credit Suisse AG now owns 844,681 shares of the company’s stock valued at $2,560,000 after buying an additional 39,940 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ObsEva by 67.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 597,899 shares of the company’s stock valued at $1,943,000 after buying an additional 241,684 shares during the period. Deutsche Bank AG raised its stake in shares of ObsEva by 499.4% during the second quarter. Deutsche Bank AG now owns 198,455 shares of the company’s stock valued at $601,000 after purchasing an additional 165,344 shares during the period. Finally, Millennium Management LLC raised its stake in shares of ObsEva by 448.5% during the first quarter. Millennium Management LLC now owns 196,273 shares of the company’s stock valued at $638,000 after purchasing an additional 160,488 shares during the period. Institutional investors and hedge funds own 31.71% of the company’s stock.
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Further Reading: What is the Gross Domestic Product (GDP)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.